$5.24 B
Share price
Change (1 day)
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Revenue for Lundbeck (HLUN-B.CO)

Revenue in 2023 (TTM): $2.66 B

According to Lundbeck 's latest financial reports the company's current revenue (TTM) is $2.66 B. In 2022 the company made a revenue of $2.58 B an increase over the years 2021 revenue that were of $2.55 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Lundbeck from 2009 to 2023

Annual revenue

Year Revenue Change
2023 (TTM)$2.66 B3.19%
2022$2.58 B1.24%
2021$2.55 B-7.03%
2020$2.74 B5.51%
2019$2.60 B-7.85%
2018$2.82 B5.99%
2017$2.66 B14.81%
2016$2.31 B7.19%
2015$2.16 B-8.56%
2014$2.36 B-12.76%
2013$2.71 B4.77%
2012$2.58 B-12.76%
2011$2.96 B13.7%
2010$2.60 B0.37%
2009$2.59 B